Global private equity and venture capital investments in pharmaceutical companies lag 2024 figures, and regulatory headwinds ...

There’s a crisis brewing for the next generation of venture capitalists. While Silicon Valley heavyweights like Sequoia ...

Capital raised last year to lend to growth-stage companies fell from a 17-year high as the strategy’s returns soured.

The lack of a healthy exit market is an existential problem for the venture capital industry, writes guest author Dan Gray, ...

It’s sold as just a “modest” hit to 80,000 wealthy retirees. But a leading tax expert says Jim Chalmers’ superannuation ...

The private equity (PE) industry has long been defined by its twin pillars: venture capital (VC) for funding disruptive ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

After two years of decline, India's private equity and venture capital investments rebounded in 2024, growing by 9% to $43 billion across 1,600 deals. This resurgence, driven by VC and growth ...

Hercules Capital focuses on technology sector, with portfolio value of $3.9 billion and low non-accrual ratio of 0.5%. Click ...

The financial technology (fintech) sector is transforming how private equity (PE) and venture capital (VC) firms operate in Australia. With advancements in artificial intelligence, blockchain, and ...

The stakes of Hinge Health's investors and executives are now worth millions after the company debuted on the stock market.

The broader conditions that shaped 2023, including tight capital, cautious investors, and high borrowing costs, never went ...